Cilostazol

Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50 = 0.2 µM for the platelet enzyme). It is selective for PDE3A over PDE1, -2, -4, and -5 (IC50s = >5 µM for all). Cilostazol inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively). In vivo, cilostazol (30 mg/kg) reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism. It reduces cardiac fibrosis and prevents the development of diastolic dysfunction and cardiac hypertrophy induced by a high-fat diet and angiotensin II in mice. Formulations containing cilostazol have been used in the treatment of the symptoms of intermittent claudication in peripheral vascular disease.Formal Name: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone. CAS Number: 73963-72-1. Synonyms: OPC 13013, OPC 21, Pletaal, Pletal. Molecular Formula: C20H27N5O2. Formula Weight: 369.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 12.5 mg/ml, DMSO: 12.5 mg/ml, DMSO:PBS (pH 7.2) (1:7): 0.13 mg/ml, Ethanol: 0.11 mg/ml. lambdamax: 257 nm. SMILES: O=C(N1[H])CCC2=C1C=CC(OCCCCC3=NN=NN3C4CCCCC4)=C2. InChi Code: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26). InChi Key: RRGUKTPIGVIEKM-UHFFFAOYSA-N.